ERBB2 and breast neoplasm: Disease recurrence in patients with the early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast tumor subtype is particularly challenging to manage due to its complex and very heterogeneous biological nature.